Cereno Scientific

Based in Sweden, Cereno Scientific is focused on the development of innovative, effective and safe treatments for people with rare cardiovascular and pulmonary diseases. Lead asset CS1, an HDAC inhibitor that acts as an epigenetic modulator, is currently being investigated in a Phase II clinical trial for the treatment of PAH.

Equities

Equities by Sector

Sectors

Thematics

Latest

Inside the mind of investors: Oberon Investments

UK equities: Not wrong to call them, but Europe surprised

MediaWatch – What now?

Audiovisual

Latest

Take on Trusts – March 2025

Patria Private Equity Trust in 60 seconds

OSE Immunotherapeutics — Lusvertikimab and the future of IBD: KOL insights post-ECCO webinar

About Edison

About Edison

Careers

Cereno Scientific (OMX: CRNO-B)

Latest Insights

Cereno Scientific — Poised for active year in CVD and rare diseases

Cereno Scientific — CS014 achieves another Phase I milestone

Cereno Scientific – executive interview

Cereno Scientific — A productive period with plenty more to come

Sector

Equity Analyst

Key Management

Research

Cereno Scientific — Pressing clinical assets forward to key inflection

Cereno Scientific — CS1 Phase II results inbound; first dose of CS014

Cereno Scientific — CS1 granted OMPD, complementing FDA ODD

Cereno Scientific — CS014 (second asset) crosses into the clinic

Cereno Scientific — All eyes on Q3 readout after Q1 update

Cereno Scientific — CS014 (thrombosis) progresses towards the clinic

Cereno Scientific – Executive interview with CSO and CMO

Cereno Scientific – executive interview

Cereno Scientific — Differentiated approach in CVD with potential

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time